-
公开(公告)号：US20090124695A1
公开(公告)日：2009-05-14
申请号：US12271798
申请日：2008-11-14
IPC分类号： A61K31/202 , C07C61/35 , C12N5/06
CPC分类号： C07C405/00
摘要： A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
-
2.发明授权Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolites 失效四环素前列腺素D，J，E，A和F代谢物的制备方法公开(公告)号：US08680327B2
公开(公告)日：2014-03-25
申请号：US13160483
申请日：2011-06-14
IPC分类号： C07C405/00 , C07C51/347 , C07C59/82
CPC分类号： C07C405/00 , C07C51/377 , C07C59/82
摘要： The present invention generally relates to synthetic methods for preparing tetranor-prostaglandin D, J, E, A, and F metabolites.
摘要翻译： 本发明一般涉及制备四倍体前列腺素D，J，E，A和F代谢物的合成方法。
-
公开(公告)号：US08536185B2
公开(公告)日：2013-09-17
申请号：US12564582
申请日：2009-09-22
申请人： Gregory W. Endres , Pil Heui Lee , Kirk Lang Olson , James Bernard Kramer , Fred Lawrence Ciske , Stephen Douglas Barrett
发明人： Gregory W. Endres , Pil Heui Lee , Kirk Lang Olson , James Bernard Kramer , Fred Lawrence Ciske , Stephen Douglas Barrett
IPC分类号： A61K31/44 , C07D401/04 , C07D239/42 , C07D239/02
CPC分类号： C07D401/04 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D407/14 , C07D413/04 , C07D417/04 , C07D417/14
摘要： Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
-
4.发明授权Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase 有权用于测定化合物或试剂替代造血前列腺素D合酶的有效配体的能力的方法公开(公告)号：US08440417B2
公开(公告)日：2013-05-14
申请号：US12465332
申请日：2009-05-13
IPC分类号： G01N21/00 , G01N33/53 , G01N33/542
CPC分类号： C12Q1/533 , C07D213/82 , C07D239/28 , C07D277/56 , C07D405/12 , C07D491/22 , C12N9/1088 , G01N2500/04 , Y10T436/10
摘要： An exemplary embodiment may be directed to a fluorescence polarization assay that screens compounds or agents for their affinity to hematopoietic prostaglandin D synthase (H-PGDS) based on their ability to displace a fluorophore-containing detection analyte bound to an enzyme comprising the primary amino acid sequence of H-PGDS. Another exemplary embodiment utilizes an enzyme having a maltose binding protein amino-acid sequence fused with an N-terminus of the enzyme.
摘要翻译： 一个示例性实施方案可以针对荧光偏振测定法，其基于它们将含荧光团的检测分析物结合到包含第一氨基酸的酶的能力来筛选化合物或试剂对造血前列腺素D合成酶（H-PGDS）的亲和力 H-PGDS序列。 另一个示例性实施方案使用具有与酶的N末端融合的麦芽糖结合蛋白氨基酸序列的酶。
-
5.发明授权Prostaglandin E1 and E2 analogs for the treatment of various medical conditions 有权前列腺素E1和E2类似物用于治疗各种医疗条件公开(公告)号：US08063240B2
公开(公告)日：2011-11-22
申请号：US12271764
申请日：2008-11-14
申请人： Nancy S. Barta , Stephen D. Barrett , Gregory W. Endres , Andriy M. Kornilov , Kirk M. Maxey , Adam Uzieblo
发明人： Nancy S. Barta , Stephen D. Barrett , Gregory W. Endres , Andriy M. Kornilov , Kirk M. Maxey , Adam Uzieblo
CPC分类号： C07C405/00
摘要： A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
摘要翻译： 具有对EP受体的选择性并表现出EP激动剂活性的前列腺素类似物，其可用于扩展造血干细胞群体或治疗或预防流感，骨折，骨病，青光眼，眼高血压，痛经，早产，免疫功能障碍 ，骨质疏松症，哮喘，过敏，男性性功能障碍，女性性功能障碍，牙周病，胃溃疡，肾脏疾病或其他EP受体介导的病症。
-
6.发明申请MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES 有权多中心化合物作为H-PGDS的抑制剂及其用于治疗PROSTAGLANDIN D2介导的疾病公开(公告)号：US20100075990A1
公开(公告)日：2010-03-25
申请号：US12564582
申请日：2009-09-22
申请人： Gregory W. Endres , Pil Heui Lee , Kirk Lang Olson , James Bernard Kramer , Fred Lawrence Ciske , Stephen Douglas Barrett
发明人： Gregory W. Endres , Pil Heui Lee , Kirk Lang Olson , James Bernard Kramer , Fred Lawrence Ciske , Stephen Douglas Barrett
IPC分类号： A61K31/495 , C07D401/04 , C07D239/02 , A61K31/44 , A61P37/04
CPC分类号： C07D401/04 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D407/14 , C07D413/04 , C07D417/04 , C07D417/14
摘要： Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
摘要翻译： 多杂芳基化合物，它们的制备方法，包含这些化合物的药物组合物及其在预防和治疗前列腺素D2介导的疾病和可通过抑制造血前列腺素D合成酶（H-PGDS）调节的病症）中的药物用途。
-
7.发明申请METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE 有权用于测定化合物或试剂的方法，用于排除HEMATOPOIETIC PROSTAGLANDIN D合成酶的重要配体公开(公告)号：US20090286261A1
公开(公告)日：2009-11-19
申请号：US12465332
申请日：2009-05-13
IPC分类号： G01N33/53 , C12N9/00 , C07D239/02 , C07D213/81 , C07D241/04 , C07D403/00 , C07D277/20
CPC分类号： C12Q1/533 , C07D213/82 , C07D239/28 , C07D277/56 , C07D405/12 , C07D491/22 , C12N9/1088 , G01N2500/04 , Y10T436/10
摘要： An exemplary embodiment may be directed to a fluorescence polarization assay that screens compounds or agents for their affinity to hematopoietic prostaglandin D synthase (H-PGDS) based on their ability to displace a fluorophore-containing detection analyte bound to an enzyme comprising the primary amino acid sequence of H-PGDS. Another exemplary embodiment utilizes an enzyme having a maltose binding protein amino-acid sequence fused with an N-terminus of the enzyme.
摘要翻译： 一个示例性实施方案可以针对荧光偏振测定法，其基于它们将含荧光团的检测分析物结合到包含第一氨基酸的酶的能力来筛选化合物或试剂对造血前列腺素D合成酶（H-PGDS）的亲和力 H-PGDS序列。 另一个示例性实施方案使用具有与酶的N末端融合的麦芽糖结合蛋白氨基酸序列的酶。
-
公开(公告)号：US08450326B2
公开(公告)日：2013-05-28
申请号：US12564582
申请日：2009-09-22
申请人： Gregory W. Endres , Pil Heui Lee , Kirk Lang Olson , James Bernard Kramer , Fred Lawrence Ciske , Stephen Douglas Barrett
发明人： Gregory W. Endres , Pil Heui Lee , Kirk Lang Olson , James Bernard Kramer , Fred Lawrence Ciske , Stephen Douglas Barrett
IPC分类号： A61K31/44 , C07D401/04 , C07D239/42 , C07D239/02
摘要： Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
-
9.发明申请METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES 失效方法制备TETRANOR-PROSTAGLANDIN D，J，E，A和F代谢物公开(公告)号：US20120041229A1
公开(公告)日：2012-02-16
申请号：US13160483
申请日：2011-06-14
IPC分类号： C07C405/00
CPC分类号： C07C405/00 , C07C51/377 , C07C59/82
摘要： The present invention generally relates to synthetic methods for preparing tetranor-prostaglandin D, J, E, A, and F metabolites.
摘要翻译： 本发明一般涉及制备四倍体前列腺素D，J，E，A和F代谢物的合成方法。
-
10.发明申请PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS 有权PROSTAGLANDIN E1和E2模拟物治疗各种医疗条件公开(公告)号：US20090221654A1
公开(公告)日：2009-09-03
申请号：US12271764
申请日：2008-11-14
申请人： Nancy S. Barta , Stephen D. Barrett , Gregory W. Endres , Andrei M. Kornilov , Kirk M. Maxey , Adam Uzieblo
发明人： Nancy S. Barta , Stephen D. Barrett , Gregory W. Endres , Andrei M. Kornilov , Kirk M. Maxey , Adam Uzieblo
IPC分类号： A61K31/428 , C07D333/52 , A61K31/381 , A61K31/19 , C07C59/00 , C07D277/62
CPC分类号： C07C405/00
摘要： A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
摘要翻译： 具有对EP受体的选择性并表现出EP激动剂活性的前列腺素类似物，其可用于扩展造血干细胞群体或治疗或预防流感，骨折，骨病，青光眼，眼高血压，痛经，早产，免疫功能障碍 ，骨质疏松症，哮喘，过敏，男性性功能障碍，女性性功能障碍，牙周病，胃溃疡，肾脏疾病或其他EP受体介导的病症。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.026 秒)
